impact factor

Full Papers


Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature

1, 2, 3, 4, 5


  1. UCB Pharma, Raleigh, USA.
  2. UCB Pharma, Raleigh, USA.
  3. Oregon Health and Science University, Portland, USA.
  4. University of Alabama at Birmingham, USA.
  5. UCB Pharma, Raleigh, USA.

2018 Vol.36, N°2
PI 0263, PF 0274
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 29148402 [PubMed]

Received: 11/04/2017
Accepted : 01/08/2017
In Press: 14/11/2017
Published: 18/04/2018


The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates.
PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000–30 Jun 2015. Extracted information included incidence/prevalence rates, geographical population, study design, data source, case definition, age/gender, and classification criteria used.
Of 2,148 articles identified, 19, from 15 countries, fulfilled eligibility criteria. Incidence rates per 100,000 patient-years were reported in 4 AS studies and varied from 0.4 (Iceland) to 15.0 (Canada). Reported AS prevalence rates per 100,000 persons also showed considerable variation (16 studies: 6.5 [Japan] to 540.0 [Turkey]). Only 3 axSpA and no nr-axSpA prevalence rates were reported. Considerable variation was seen in the methodology used to estimate incidence and prevalence rates, e.g. screening method, study design, and classification criteria. Although the prevalence of AS is known to vary by HLA-B27 status, only 4 studies reported this genetic marker.
There is an unmet need for future studies to use consistent methodology, capture all relevant information (including HLA-B27 positivity), and investigate under-reported populations (e.g. nr-axSpA; southern hemisphere countries) to estimate the population burden of axSpA. Future studies should aim to address data gaps to provide accurate incidence/prevalence estimates for the global axSpA population.

Rheumatology Article